Digna Biotech SL-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Digna Biotech SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013076
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Digna Biotech SL (Digna) is a biotechnology company that specializes in the development and commercialization of robust clinical therapeutic candidates. The company’s pipeline portfolio includes cutaneous manifestation of scleroderma, clinical indications for kidney transplant and liver surgery, gene therapy acute intermittent prophyria and hepatitis C virus infection. Its preclinical product portfolio comprises Ischemic stroke, anti-tumor antibodies increasing antibody-dependent cell-mediated cytotoxicity against malignant cells, indications liver cirrhosis, blood loss, and liver-targeted fusion protein for treatment of cancer, and others. Digna’s therapeutic expertise includes dermatology, cardiovascular, oncology, liver diseases, and others. The company has its presence in Madrid and the US. Digna is headquartered in Pamplona, Spain.

Digna Biotech SL – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Digna Biotech SL, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Digna Biotech SL, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Digna Biotech SL, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Digna Biotech SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Digna Biotech SL, Medical Devices Deals, 2011 to YTD 2017 9
Digna Biotech SL, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Digna Biotech SL, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Hepacyl Therapeutics Secures US$3.1 Million In Venture Financing 11
Bionure Raises US$2 Million In Seed Financing 12
Partnerships 13
Flamel Technologies Enters Into Co-Development Agreement With Digna Biotech 13
Digna Biotech SL – Key Competitors 15
Digna Biotech SL – Key Employees 16
Digna Biotech SL – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Digna Biotech SL, Pharmaceuticals & Healthcare, Key Facts 2
Digna Biotech SL, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Digna Biotech SL, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Digna Biotech SL, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Digna Biotech SL, Deals By Therapy Area, 2011 to YTD 2017 8
Digna Biotech SL, Medical Devices Deals, 2011 to YTD 2017 9
Digna Biotech SL, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Hepacyl Therapeutics Secures US$3.1 Million In Venture Financing 11
Bionure Raises US$2 Million In Seed Financing 12
Flamel Technologies Enters Into Co-Development Agreement With Digna Biotech 13
Digna Biotech SL, Key Competitors 15
Digna Biotech SL, Key Employees 16
Digna Biotech SL, Other Locations 17
Digna Biotech SL, Subsidiaries 17

★海外企業調査レポート[Digna Biotech SL-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hasbro, Inc.:企業の戦略・SWOT・財務情報
    Hasbro, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hasbro, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • C. R. Bard, Inc.:企業のM&A・事業提携・投資動向
    C. R. Bard, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's C. R. Bard, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Avantec Vascular Corp:企業の製品パイプライン分析2018
    Summary Avantec Vascular Corp (Avantec Vascular), a subsidiary of Goodman Co Ltd, is a medical device company that develops cardiovascular interventional and peripheral vascular devices. The company's products comprise balloon catheter, aspiration catheter, device delivery system, micro catheter, gu …
  • Teekay Corp (TK):石油・ガス:M&Aディール及び事業提携情報
    Summary Teekay Corp (Teekay) is a provider of marine transportation services to oil and gas industry. The company transports crude oil, liquefied natural gas (LNG), liquefied petroleum gas (LPG) and other petroleum products. It also offers offshore oil production, storage and offloading services. Te …
  • Fujitsu Australia Ltd:企業の戦略的SWOT分析
    Fujitsu Australia Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Cholamandalam Investment and Finance Company Ltd (CHOLAFIN):企業の財務・戦略的SWOT分析
    Cholamandalam Investment and Finance Company Ltd (CHOLAFIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the comp …
  • Gevo, Inc.:企業のM&A・事業提携・投資動向
    Gevo, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Gevo, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • AntriaBio Inc (ANTB)-製薬・医療分野:企業M&A・提携分析
    Summary AntriaBio Inc (AntriaBio), formerly AntriaBio Delaware Inc is a biopharmaceutical company that develops drug therapies for the treatment of diabetes and metabolic diseases. The company’s lead product candidate include AB10, human recombinant insulin for use in type 1 and type 2 diabetes for …
  • Acceleron Pharma Inc (XLRN):企業の財務・戦略的SWOT分析
    Acceleron Pharma Inc (XLRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Calix Ltd (CXL):企業の財務・戦略的SWOT分析
    Calix Ltd (CXL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • HepQuant Llc:企業の製品パイプライン分析2018
    Summary Hepquant LLC (Hepquant) is a medical device company that offers diagnostic products. The company develops and markets patented and patent-pending technology for assessing liver function of patients with chronic liver disease. It offers investigational combination drug and diagnostic devices. …
  • The Singing Machine Company, Inc.:戦略・SWOT・企業財務分析
    The Singing Machine Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Singing Machine Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Pearl Global Industries Limited
    Pearl Global Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Pearl Global Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • MGB Biopharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary MGB Biopharma Ltd (MGB Biopharma) is a a biopharmaceutical company which develops novel class of anti-infectives using Minor Groove Binder (MGBs) compounds. Its lead drug candidate MGB-BP-3 in the field of antibacterial resistance is active against may Gram-positive bacteria. MGB Biopharma a …
  • CVS Health Corp (CVS):製薬・医療:M&Aディール及び事業提携情報
    Summary CVS Health Corporation (CVS) is an integrated prescription and related health services provider. The company offers a range of solutions such as prescription medications; health care products; popular beauty, health and personal care brands; retail-based health clinical services; and pharmac …
  • Ivy Cosmetics Corporation:企業の戦略・SWOT・財務分析
    Ivy Cosmetics Corporation - Strategy, SWOT and Corporate Finance Report Summary Ivy Cosmetics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Alcami Corp:企業の戦略的SWOT分析
    Alcami Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • China Everbright Ltd (165):企業の財務・戦略的SWOT分析
    China Everbright Ltd (165) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Compania Espanola de Petroleos SAU:石油・ガス:M&Aディール及び事業提携情報
    Summary Compania Espanola de Petroleos SAU (CEPSA) is an integrated energy company. It explores for, produces, refines, transports, and markets and sells crude oil, petroleum products, and natural gas. The company also generates and sells electricity and thermal power to industrial customers and con …
  • LIncoln Electric Holdings Inc:企業の戦略・SWOT・財務情報
    LIncoln Electric Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary LIncoln Electric Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆